Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate safety and efficacy (measured by clinical tumor response) of letrozole daily
dose, 2.5 mg in postmenopausal patients with primary (untreated) breast cancer.